Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines - Wikidata - awgldk - TriplyDB

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

http://www.wikidata.org/entity/Q34023749

about

Genetic instability in the tumor microenvironment: a new look at an old neighbor Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer.Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.Risk-benefit perception of pregnancy among breast cancer survivors.The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?

P2860

Q26801374-C04A1FC6-9817-4D86-B80F-A2259C87B34E Q36203408-3F62A48B-2F5E-47BD-9FD4-977D68D0A3CA Q36262855-C457A835-3242-4EDF-8B53-6CB0AAC911ED Q36421921-22017AE6-6E5D-4049-A3C8-3E0823E5FF8D Q36782669-4BDCDD51-7D60-4680-8CE5-1DE6A2023F0E Q37636623-9A51D2B7-8701-44EC-9545-05133EC8006C Q38818023-2D0F8069-9204-444F-A4E0-D239BD55BFD6 Q38821155-754E9B94-3B3B-4FC9-ADB7-9363B12DD823 Q47375125-B43DCE54-BA49-4DB3-9AF1-2A384501C770 Q47768978-AF86A0BE-E2BC-41B2-9280-745664B8397F Q48318138-52983644-3947-4B71-AAB3-7E604ACC65A6

P2860

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

http://www.wikidata.org/entity/Q34023749

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@ast

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@en

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@nl

type

label

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@ast

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@en

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@nl

prefLabel

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@ast

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@en

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@nl

P1433

Q34023749-D110D9E8-7D98-4798-A184-6C55A825FFE2

P1476

Q34023749-9A1A5C43-9267-4258-986F-60E0A056B62E

P2093

Q34023749-3BB55540-10D1-43CE-82ED-A41640A7A1E0

Q34023749-4CA48DA7-F6FF-4389-BF77-75719A61E154

Q34023749-54BE46E0-76B3-4CB8-8852-0065D8294004

P2860

Q34023749-064C3410-DCA2-4E87-8F26-148DB60943CA

Q34023749-0BF93585-A9A8-4952-AE23-F53375164E79

Q34023749-133B7B95-2102-4CA3-A046-26F6FD5523CE

Q34023749-1A456A42-E0E6-450F-9042-FFC3928828A0

Q34023749-23C2C231-299D-4AB8-8BA9-F2BEA12ACDF7

Q34023749-28A9324A-32DD-45FD-B7A2-C1FC0013D472

Q34023749-31FD19FE-7FA6-4DDE-8838-469E388E77C4

Q34023749-3545737F-37DE-40C8-9E73-47A1603827FE

Q34023749-35534CCB-050B-4A8F-9AE2-834C6FA108A4

Q34023749-37AAA822-8311-4E7D-9435-DB1EF448FA0C

P304

Q34023749-F9BA504E-D2E4-4950-A0F6-E86DD05509CE

P31

Q34023749-8894CEE0-378B-4C34-BB4B-16551E639992

P356

Q34023749-23E5C44E-B4D5-428F-BE98-186E3FEB8A27

P433

Q34023749-0EAA053E-81D3-45D7-8F91-BFBDA9963895

P478

Q34023749-DB71B08F-51FD-4C93-B7E8-5F278EDD617B

P577

Q34023749-9F1B41FB-4003-4190-9C9F-D3CF66459208

P5875

Q34023749-32013E2B-BDDF-40AB-B62B-9347BFA37641

P698

Q34023749-0C4F12DA-D4CC-435D-8F9A-D39EF9498C04

P921

Q34023749-B620684C-D98A-42CB-91D0-2272B95B2840

P932

Q34023749-2AA74314-C26A-424D-A5F8-284B567FDE92

P356

P1433

World journal of clinical oncology

P1476

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

@en

P2093

Abhisek Swaika

http://www.w3.org/2001/XMLSchema#string

Alvaro Moreno-Aspitia

http://www.w3.org/2001/XMLSchema#string

Jennifer A Crozier

http://www.w3.org/2001/XMLSchema#string

P2860

A gene-expression signature as a predictor of survival in breast cancer

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report

Risk factors for doxorubicin-induced congestive heart failure

Supervised risk predictor of breast cancer based on intrinsic subtypes

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

P304

529-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5306/WJCO.V5.I3.529

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264745571

http://www.w3.org/2001/XMLSchema#string

P698

25114866

http://www.w3.org/2001/XMLSchema#string

P921

P932

4127622

http://www.w3.org/2001/XMLSchema#string